SQ 22536An A cyclase inhibitor

SQ 22536 (CAS 17318-31-9)

SQ 22536 | CAS 17318-31-9 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_15, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.2
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_201572, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 100ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: 9-THF-Ade
Application: An A cyclase inhibitor
CAS Number: 17318-31-9
Purity: ≥99%
Molecular Weight: 205.22
Molecular Formula: C9H11N5O
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

SQ 22536 is an A cyclase inhibitor that can permeate the cell. SQ 22536 can block cAMP enhancement mediated by Cordycepin (sc-203902), an inhibitor of human platelet aggregation. In platelet studies SQ 22536 was shown to reverse the antiplatelet effects of Sesamol (sc-253552) on p38 MAPK phosphorylation and platelet aggregation, and the stimulatory effects induced by Sesamol on VASP, eNOS phosphorylation, and NO release. SQ 22536 has demonstrated inhibition of the effect of glucagon on rat membrane cyclase activity and has reduced the effect of isoproterenol, epinephrine (sc-252779), norepinephrine, and phenylephrine.


References

1. Dixon, D. and Atwood, H.L. 1989. J. Neurosci. 9: 4246-4252. PMID: 2480401
2. Lippe, C., et al. 1991. Comp. Biochem. Physiol. C, Comp. Pharmacol. Toxicol. 99: 209-211. PMID: 1711430
3. Fabbri, E., et al. 1991. J. Enzym. Inhib. 5: 87-98. PMID: 1669444
4. Goldsmith, B.A., et al. 1991. Proc. Natl. Acad. Sci. U.S.A. 88: 9021-9025. PMID: 1924365
5. Cho, H.J., et al. 2007. Eur. J. Pharmacol. 558: 43-51. PMID: 17229422
6. Belkacemi, L., et al. 2008. Life Sci. 82: 1272-1280. PMID: 18538351
7. Chang, C.C., et al. 2009. J Nutr Biochem. PMID: 20015631

Physical State :
Solid
Solubility :
Soluble in ethanol, water (25 mg/ml), and DMSO (50 mM).
Storage :
Store at -20° C
Melting Point :
171.94° C (Predicted)
Boiling Point :
~474.8° C at 760 mmHg (Predicted)
Density :
~1.7 g/cm3 (Predicted)
Refractive Index :
n20D 1.83
IC50 :
PTH-stimulation of adenylate cyclase: IC50 = 200 µM; cAMP production induced by prostaglandin E1: IC50 = 82 µM (platelet lysates); cAMP production induced by prostaglandin E1: IC50 = 1 µM (intact platelets); Adenylyl cyclase: IC50 = 1.4 µM; PI4-kinase alpha subunit: IC50 = 28.2 µM (human)
Ki Data :
Adenosine A2b receptor: Ki= 2400 nM (Rattus norvegicus); PI4-kinase type II beta: Ki= 21.2 µM (human); PI4-kinase alpha subunit: Ki= 21.2 µM (human); Adenosine A1 receptor: Ki= 28 µM (Rattus norvegicus); Adenosine A2b receptor: Ki= 23 (Rattus norvegicus)
pK Values :
pKb: 3.82
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
5270
MDL Number :
MFCD00210216
SMILES :
C1CC(OC1)N2C=NC3=C2N=CN=C3N

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

SQ 22536  Product Citations

See how others have used SQ 22536. Click on the entry to view the PubMed entry .

Citations 1 to 10 of 10 total

PMID: # 27318925  2016. Naunyn Schmiedebergs Arch. Pharmacol.

PMID: # 26675132  2015. Sci Rep. 5: 18325.

PMID: # 26716691  2015. PLoS ONE. 10: e0145522.

PMID: # 24642449  Grailer, JJ. et al. 2014. J Innate Immun. 6: 607-18.

PMID: # 24353062  Becker, JR. et al. 2014. Development (Cambridge, England). 141: 335-45.

PMID: # 24091307  Bitterman, JL. et al. 2013. J. Pharmacol. Exp. Ther. 347: 589-98.

PMID: # 22318967  Bosmann, M. et al. 2012. FASEB J. 26: 2137-44.

PMID: # 21621583  2011. Biochimie. 93: 1510-9.

PMID: # 22057271  Xie, Z. et al. 2011. J. Biol. Chem. 286: 44646-58.

PMID: # 25715600  Ermakov, AM. et al. Biofizika. 59: 552-7.

Citations 1 to 10 of 10 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 58ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Chang Chang, CC. et al. (PubMed 20015631) found that SQ 22536, an inhibitor of adenylate cyclase, markedly reversed the sesamol-mediated inhibitory effects on platelet aggregation and p38 MAPK phosphorylation, and sesamol-mediated stimulatory effects on VASP and eNOS phosphorylation, and NO release in mice. -SCBT Publication Review
Date published: 2015-05-29
  • y_2019, m_11, d_15, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.2
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_201572, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 37ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.